Jill Beraud Net Worth

The estimated Net Worth of Jill Beraud is at least $240 Mille dollars as of 26 January 2015. Ms. Beraud owns over 500 units of Revance Therapeutics Inc stock worth over $3,290 and over the last 10 years she sold RVNC stock worth over $0. In addition, she makes $236,750 as Independent Director at Revance Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Beraud RVNC stock SEC Form 4 insiders trading

Jill has made over 1 trades of the Revance Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 500 units of RVNC stock worth $45,355 on 26 January 2015.

The largest trade she's ever made was buying 500 units of Revance Therapeutics Inc stock on 26 January 2015 worth over $45,355. On average, Jill trades about 16 units every 0 days since 2015. As of 26 January 2015 she still owns at least 500 units of Revance Therapeutics Inc stock.

You can see the complete history of Ms. Beraud stock trades at the bottom of the page.

Jill Beraud biography

Jill Beraud serves as Independent Director of the Company. Ms. Beraud is currently CEO and Co-Founder of Sh'nnong Beverage Company, a business creating a line of functional beverages. Prior to that, she served as CEO of IPPOLITA, a fine jewelry company with distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom, and other national retailers. Previously she held the role of Executive Vice President, Global Retail and e-Commerce, for Tiffany & Co., where she was responsible for all global retail, operations, e-commerce, digital, and omni-channel consumer experience. Ms. Beraud has also managed brands such as Living Proof and Starbucks/Lipton Joint Ventures, and served as global chief marketing officer at PepsiCo, where she was responsible for PepsiCo's $60 billion portfolio of food and beverage brands. She also spent 13 years at Limited Brands as chief marketing officer of Victoria's Secret, and Executive Vice President of Marketing for its broader portfolio of specialty brands, including Bath & Body Works, Henri Bendel, and Limited Stores. Further, she has a long history of serving on boards of renowned brands, such as Levi Strauss & Co. and Elizabeth Arden Holdings. Ms. Beraud was named to Fast Company's "Most Creative People in Business" in 2013.

What is the salary of Jill Beraud?

As the Independent Director of Revance Therapeutics Inc, the total compensation of Jill Beraud at Revance Therapeutics Inc is $236,750. There are 9 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.

How old is Jill Beraud?

Jill Beraud is 59, she's been the Independent Director of Revance Therapeutics Inc since 2019. There are 6 older and 9 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.

What's Jill Beraud's mailing address?

Jill's mailing address filed with the SEC is C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO, CA, 94111.

Insiders trading at Revance Therapeutics Inc

Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli e Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.

What does Revance Therapeutics Inc do?

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form

Complete history of Ms. Beraud stock trades at Revance Therapeutics Inc, Tiffany & Co e Levi Strauss & Co

Revance Therapeutics Inc executives and stock owners

Revance Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Foley,
  President, Chief Executive Officer, Director
• Abhay Joshi,
  Chief Operating Officer, President - R&D and Product Operations
• Tobin Schilke,
  Chief Financial Officer
• Mark J. Foley,
  CEO & Director
• Dustin Sjuts,
  Chief Commercial Officer, Aesthetics & Therapeutics
• Dr. Abhay Joshi,
  COO, Pres of R&D and Product Operations
• Dustin S. Sjuts,
  Pres
• Tobin C. Schilke,
  CFO & Principal Accounting Officer
• Chris Nolet,
  Independent Director
• Jill Beraud,
  Independent Director
• Angus Russell,
  Independent Chairman of the Board
• Robert Byrnes,
  Independent Director
• Philip Vickers,
  Independent Director
• Phyllis Gardner,
  Independent Director
• Julian Gangolli,
  Independent Director
• Jeanie Herbert,
  Sr. Director, Investor Relations
• Aubrey Rankin,
  Director
• Dwight Moxie,
  Senior Vice President, General Counsel, Corporate Secretary
• Azita Nejad,
  Sr. VP of Technical Operations
• Justin Ford,
  Sr. VP of HR & Head of People
• Taryn Conway,
  VP of Marketing
• Jessica Serra,
  Head of Investor Relations & ESG
• L Daniel Browne,
  CEO and President
• James Walter Glasheen,
  Director
• Ronald W Eastman,
  Director
• Mark A Sr Prygocki,
  Director
• Todd Erik Zavodnick,
  CCO & President,
• Cyril Allouche,
  Principal Accounting Officer
• Caryn Gordon Mc Dowell,
  SVP, GC & Secretary
• Jacob Waugh,
  Chief Scientific Officer
• Jonathan Tunnicliffe,
  Director
• Ronald J Wooten,
  Director
• Woodlands Health Ventures F...,
  
• Arthur Peter Bertolino,
  EVP and Chief Medical Officer
• Pharma Opportunities Fund I...,
  
• Lauren P Silvernail,
  CFO, Secretary & EVP Corp Dev.
• Curtis Ruegg,
  EVP, Technical Operations
• Olivia C Ware,
  Director
• Carey O Connor Kolaja,
  Director
• Erica Jordan,
  Chief Commercial Officer
• Vlad Coric,
  Director